Analysis of top Seeking Alpha coverage: Clovis Oncology
Today we will discuss Clovis Oncology (CLVS). Clovis Oncology have had a good run this week, gaining more than 11%. The stock though still remains down more than 21% in the last six months and well-off its 52-week high of $99.45.
The gains this week have been driven by Clovis’ announcement that it received positive trend vote from the European Medicines Agency’s ((EMA)) Committee for Medicinal Products for Human Use ((CHMP)) for rucaparib’s Marketing Authorization Application ((MAA)) as a monotherapy or the treatment of a